Sanofi Company History

This timeline chronicles the remarkable journey of Sanofi, a global leader in the pharmaceutical industry, driven by strategic mergers and acquisitions. Sanofi was founded in 1973 from the French oil and chemicals sector, expanding its pharmaceutical portfolio through organic growth and smaller partnerships. A pivotal merger with Synthélabo in 1999 marked the beginning of a transformative era. The merger of Sanofi-Synthélabo with Aventis in 2004 created Sanofi-Aventis, significantly enhancing global reach (US, Europe, Asia). Major acquisitions strengthened Sanofi’s focus on specialty care and immunology: Genzyme (2011, $20B, added rare disease drugs: Cerezyme, Fabrazyme), Bioverativ (2018, $11.6B, added hemophilia drugs: Eloctate, Alprolix), Ablynx (2018, $4.8B, added nanobody platform), Principia (2020, $3.7B, added BTK inhibitors for multiple sclerosis). These expanded Sanofi’s portfolio in rare diseases, multiple sclerosis, immunology, and oncology. Sanofi also invested in vaccines (polio, flu, meningitis, RSV), diabetes (Lantus, Toujeo), and consumer health. Today, Sanofi continues to reshape its portfolio, emphasizing innovative medicines (Dupixent – immunology, oncology, rare diseases) and vaccines, while pursuing strategic partnerships (Translate Bio, mRNA; Kymera, protein degradation) to sustain growth momentum. Sanofi’s vision focuses on science-driven innovation, digital transformation, and global health access.

PlotWizard Abonnieren

他的近期作品集 查看更多>>

Aktuelle Werke Weitere Werke anzeigen>>